Picture of Orexo AB logo

ORX Orexo AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Brief: Positive Results From Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations For Opioid Overdose Reversal

June 30 (Reuters) - Orexo AB  ORX.ST :
    * POSITIVE RESULTS FROM HUMAN PK STUDY ASSESSING OREXO'S
INTRANASAL NALMEFENE FORMULATIONS FOR OPIOID OVERDOSE REVERSAL
    * PRELIMINARY RESULTS INDICATE EXTENSIVE AND RAPID
ABSORPTION
ACROSS ALL THREE OX125 FORMULATIONS AS WELL AS GOOD
TOLERABILITY, SUPPORTING VIABILITY OF OX125 AS A RESCUE
MEDICATION FOR OPIOID OVERDOSE

Source text for Eikon:  ID:nWkr2WXfTl 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587785110;))

Recent news on Orexo AB

See all news